Endurant Capital Management’s Viking Therapeutics VKTX Stock Holding History

Endurant Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,754	Closed	-$336K	–	57
2023 Q2	$336K	Sell	20,754 -36,289	-64%	-$760K	0.29%	34
2023 Q1	$950K	Sell	57,043 -375,992	-87%	-$3.88M	0.49%	39
2022 Q4	$4.07M	Buy	+433,035	New	+$1.93M	1.65%	17
2019 Q2	–	Sell	-178,448	Closed	-$1.77M	–	78
2019 Q1	$1.77M	Buy	178,448 +124,982	+234%	+$1.05M	0.7%	42
2018 Q4	$409K	Sell	53,466 -18,511	-26%	-$221K	0.22%	47
2018 Q3	$1.25M	Buy	71,977 +11,478	+19%	+$137K	0.56%	41
2018 Q2	$574K	Sell	60,499 -58,601	-49%	-$390K	0.25%	55
2018 Q1	$520K	Buy	+119,100	New	+$659K	0.19%	65

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Endurant Capital Management's VKTX Position: Q3 2023 in Review

Endurant Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2023, closing a stake of 20,754 shares — an estimated $336K sold.

Endurant Capital Management first reported a position in VKTX in Q1 2018 and held it in 8 quarters. The position peaked at $4.07M in Q4 2022. 179 funds tracked by Wall St. Rank hold VKTX as of Q3 2023.

Endurant Capital Management reported no remaining Viking Therapeutics position as of Q3 2023 after selling out during the quarter.
Endurant Capital Management sold 20,754 Viking Therapeutics shares in Q3 2023, an estimated $336K.
Endurant Capital Management first reported a position in Viking Therapeutics in Q1 2018 and held it in 8 quarters.
Endurant Capital Management's Viking Therapeutics position peaked at $4.07M in Q4 2022.
179 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2023.

Based on Endurant Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.